Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC

Condition:   Oropharyngeal Squamous Cell Carcinoma
Interventions:   Radiation: Radiation;   Drug: Cisplatin;   Drug: Durvalumab;   Drug: Tremelimumab
Sponsors:   Canadian Cancer Trials Group;   AstraZeneca
Not yet recruiting

http://ift.tt/2DytMVe